Chronic obstructive pulmonary disease in severe mental illness: A timely diagnosis to advance the process of quitting smoking.
COPD
bipolar disorder
early detection
schizophrenia
smoking
Journal
European psychiatry : the journal of the Association of European Psychiatrists
ISSN: 1778-3585
Titre abrégé: Eur Psychiatry
Pays: England
ID NLM: 9111820
Informations de publication
Date de publication:
26 02 2021
26 02 2021
Historique:
pubmed:
27
2
2021
medline:
20
11
2021
entrez:
26
2
2021
Statut:
epublish
Résumé
This study has two main objectives: to describe the prevalence of undetected chronic obstructive pulmonary disease (COPD) in a clinical sample of smokers with severe mental illness (SMI), and to assess the value of the Tobacco Intensive Motivational Estimated Risk tool, which informs smokers of their respiratory risk and uses brief text messages to reinforce intervention. A multicenter, randomized, open-label, and active-controlled clinical trial, with a 12-month follow-up. Outpatients with schizophrenia (SZ) and bipolar disorder were randomized either to the experimental group-studied by spirometry and informed of their calculated lung age and degree of obstruction (if any)-or to the active control group, who followed the 5 A's intervention. The study sample consisted of 160 patients (71.9% SZ), 78.1% of whom completed the 12-month follow-up. Of the patients who completed the spirometry test, 23.9% showed evidence of COPD (77.8% in moderate or severe stages). TIMER was associated with a significant reduction in tobacco use at week 12 and in the long term, 21.9% of patients reduced consumption and 14.6% at least halved it. At week 48, six patients (7.3%) allocated to the experimental group achieved the seven-day smoking abstinence confirmed by CO (primary outcome in terms of efficacy), compared to three (3.8%) in the control group. In this clinical pilot trial, one in four outpatients with an SMI who smoked had undiagnosed COPD. An intensive intervention tool favors the early detection of COPD and maintains its efficacy to quit smoking, compared with the standard 5 A's intervention.
Sections du résumé
BACKGROUND
This study has two main objectives: to describe the prevalence of undetected chronic obstructive pulmonary disease (COPD) in a clinical sample of smokers with severe mental illness (SMI), and to assess the value of the Tobacco Intensive Motivational Estimated Risk tool, which informs smokers of their respiratory risk and uses brief text messages to reinforce intervention.
METHOD
A multicenter, randomized, open-label, and active-controlled clinical trial, with a 12-month follow-up. Outpatients with schizophrenia (SZ) and bipolar disorder were randomized either to the experimental group-studied by spirometry and informed of their calculated lung age and degree of obstruction (if any)-or to the active control group, who followed the 5 A's intervention.
RESULTS
The study sample consisted of 160 patients (71.9% SZ), 78.1% of whom completed the 12-month follow-up. Of the patients who completed the spirometry test, 23.9% showed evidence of COPD (77.8% in moderate or severe stages). TIMER was associated with a significant reduction in tobacco use at week 12 and in the long term, 21.9% of patients reduced consumption and 14.6% at least halved it. At week 48, six patients (7.3%) allocated to the experimental group achieved the seven-day smoking abstinence confirmed by CO (primary outcome in terms of efficacy), compared to three (3.8%) in the control group.
CONCLUSION
In this clinical pilot trial, one in four outpatients with an SMI who smoked had undiagnosed COPD. An intensive intervention tool favors the early detection of COPD and maintains its efficacy to quit smoking, compared with the standard 5 A's intervention.
Identifiants
pubmed: 33632347
doi: 10.1192/j.eurpsy.2021.12
pii: S0924933821000122
pmc: PMC8057420
doi:
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e22Références
World Psychiatry. 2014 Jun;13(2):153-60
pubmed: 24890068
Lancet Psychiatry. 2017 Apr;4(4):295-301
pubmed: 28237639
Nicotine Tob Res. 2010 Oct;12 Suppl:S4-11
pubmed: 20889479
JAMA Psychiatry. 2015 Dec;72(12):1172-81
pubmed: 26509694
Eur Addict Res. 2019;25(5):256-262
pubmed: 31163435
Lancet. 2016 Jun 18;387(10037):2507-20
pubmed: 27116918
Addiction. 2017 Apr;112(4):673-682
pubmed: 27943511
Gen Hosp Psychiatry. 2014 Mar-Apr;36(2):172-6
pubmed: 24360836
J Subst Abuse Treat. 2010 Jun;38(4):384-93
pubmed: 20363089
Schizophr Res. 2019 Oct;212:121-125
pubmed: 31395488
Acta Psychiatr Scand. 2015 Jun;131(6):417-25
pubmed: 25735195
Am J Respir Crit Care Med. 2017 Mar 1;195(5):557-582
pubmed: 28128970
Psychiatry Res. 2014 Dec 15;220(1-2):58-62
pubmed: 24999175
World Psychiatry. 2017 Feb;16(1):30-40
pubmed: 28127922
Schizophr Res. 2016 Oct;176(2-3):272-280
pubmed: 27237598
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Postgrad Med J. 2010 Jan;86(1011):26-33; quiz 31-2
pubmed: 20065338
BMC Psychiatry. 2017 Jul 14;17(1):252
pubmed: 28705244
Hum Genet. 2012 Jun;131(6):877-901
pubmed: 22190153
Acta Psychiatr Scand. 2006 Apr;113(4):298-305
pubmed: 16638074
Eur Respir J. 2018 Dec 6;52(6):
pubmed: 30309976
Clin Psychopharmacol Neurosci. 2015 Apr 30;13(1):1-11
pubmed: 25912533
Chest. 2003 Jun;123(6):1916-23
pubmed: 12796168
Med Clin (Barc). 2002 Sep 28;119(10):366-71
pubmed: 12372167
World Psychiatry. 2011 Feb;10(1):52-77
pubmed: 21379357
JAMA Psychiatry. 2013 Sep;70(9):931-9
pubmed: 23863861
Acta Psychiatr Scand. 2015 Aug;132(2):122-30
pubmed: 25754402
Am J Respir Crit Care Med. 2013 Feb 15;187(4):347-65
pubmed: 22878278
JAMA Intern Med. 2014 Dec;174(12):1928-9
pubmed: 25317605
Acta Psychiatr Scand. 2020 May;141(5):399-400
pubmed: 32324252
Addict Behav. 2011 Mar;36(3):261-4
pubmed: 21146317
Lancet Psychiatry. 2015 May;2(5):395-402
pubmed: 26360283
Br J Psychiatry. 2015 Jul;207(1):37-45
pubmed: 25858177
Adicciones. 2019 Apr 01;31(2):136-146
pubmed: 30059580
PLoS One. 2018 Feb 22;13(2):e0193143
pubmed: 29470502
J Consult Clin Psychol. 1995 Jun;63(3):388-99
pubmed: 7608351
JAMA Psychiatry. 2015 Apr;72(4):334-41
pubmed: 25671328
Schizophr Bull. 2012 May;38(3):543-51
pubmed: 21041835
Med Clin (Barc). 2003 May 17;120(18):693-700
pubmed: 12781095
Cochrane Database Syst Rev. 2016 Apr 10;4:CD006611
pubmed: 27060875
Addiction. 2000 Jan;95 Suppl 1:S13-7
pubmed: 10723817
JAMA. 2014 Jan 8;311(2):172-82
pubmed: 24399556
Lancet Psychiatry. 2019 May;6(5):379-390
pubmed: 30975539
Nicotine Tob Res. 2011 Nov;13(11):1161-6
pubmed: 21551248
Trials. 2019 Jan 14;20(1):47
pubmed: 30642365
Schizophr Res. 2016 Oct;176(2-3):566-571
pubmed: 27262384
Subst Use Misuse. 2014 Aug;49(10):1332-9
pubmed: 24758706
Respir Res. 2018 Sep 17;19(1):177
pubmed: 30223834
Thorax. 2009 Oct;64(10):863-8
pubmed: 19553233
BMJ. 2008 Mar 15;336(7644):598-600
pubmed: 18326503
Br Med J. 1977 Jun 25;1(6077):1645-8
pubmed: 871704
Bipolar Disord. 2009 Mar;11(2):154-65
pubmed: 19267698
COPD. 2018 Dec;15(6):612-620
pubmed: 30714418
Thorax. 2006 Oct;61(10):869-73
pubmed: 16809415
Br J Psychiatry. 2017 Sep;211(3):175-181
pubmed: 28684403
Int J Qual Health Care. 2018 Jun 1;30(5):351-357
pubmed: 29432585
Psychiatry Res. 1994 Jul;53(1):31-40
pubmed: 7991730
BMC Public Health. 2014 Jul 28;14:761
pubmed: 25074396